Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Decoding the PITX2-controlled genetic network in atrial fibrillation
Jeffrey D. Steimle, Francisco J. Grisanti Canozo, Minjun Park, Zachary A. Kadow, Md. Abul Hassan Samee, James F. Martin
Jeffrey D. Steimle, Francisco J. Grisanti Canozo, Minjun Park, Zachary A. Kadow, Md. Abul Hassan Samee, James F. Martin
View: Text | PDF
Resource and Technical Advance Cardiology

Decoding the PITX2-controlled genetic network in atrial fibrillation

  • Text
  • PDF
Abstract

Atrial fibrillation (AF), the most common sustained cardiac arrhythmia and a major risk factor for stroke, often arises through ectopic electrical impulses derived from the pulmonary veins (PVs). Sequence variants in enhancers controlling expression of the transcription factor PITX2, which is expressed in the cardiomyocytes (CMs) of the PV and left atrium (LA), have been implicated in AF predisposition. Single nuclei multiomic profiling of RNA and analysis of chromatin accessibility combined with spectral clustering uncovered distinct PV- and LA-enriched CM cell states. Pitx2-mutant PV and LA CMs exhibited gene expression changes consistent with cardiac dysfunction through cell type–distinct, PITX2-directed, cis-regulatory grammars controlling target gene expression. The perturbed network targets in each CM were enriched in distinct human AF predisposition genes, suggesting combinatorial risk for AF genesis. Our data further reveal that PV and LA Pitx2-mutant CMs signal to endothelial and endocardial cells through BMP10 signaling with pathogenic potential. This work provides a multiomic framework for interrogating the basis of AF predisposition in the PVs of humans.

Authors

Jeffrey D. Steimle, Francisco J. Grisanti Canozo, Minjun Park, Zachary A. Kadow, Md. Abul Hassan Samee, James F. Martin

×

Figure 5

Aberrant cross-signaling between CMs and endothelium/endocardium in Pitx2 mutant LA and PV.

Options: View larger image (or click on image) Download as PowerPoint
Aberrant cross-signaling between CMs and endothelium/endocardium in Pitx...
(A) Top 4 differentially expressed (control vs. Pitx2 mutant) networks identified for CMs. (B) Ligand-receptor expression in CMs, endocardium (EndoC), and endothelium (Endo). Boxed pairs demonstrate significant differential expression between controls (Ctrl) and Pitx2 mutants (Mut). (C) Predicted upstream regulators identified by Ingenuity Pathway Analysis (IPA) for differentially expressed genes (DEGs) comparing controls and Pitx2 mutants for Endo (left) and EndoC (right). A positive z score predicts addition or activation while negative z score predicts subtraction or inhibition of a pathway or ligand. A complete list of DEGs can be found in Supplemental Table 8. (D) Top 20 GO terms for up- and downregulated DEGs for Endo and EndoC. Complete details and child terms can be found in Supplemental Table 9.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts